Business
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026 Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL) Completed a $50 million registered direct financing in January 2026 Strong balanc
About this update from Foghorn Therapeutics Inc.
[{"type":"image","alt":"Foghorn Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Foghorn Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ql7RNPJuQ1jhwreokk4ggw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75}},"lazy":false},{"type":"text","content":"FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)","length":156,"tagName":"p"},{"type":"text","content":"Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026","length":107,"tagName":"p"},{"type":"text","content":"Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)","length":153,"tagName":"p"},{"type":"text","content":"Completed a $50 million registered direct financing in January 2026","length":72,"tagName":"p"},{"type":"text","content":"Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of the January 2026 financing, the company has cash runway into the first half of 2028","length":223,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-K filing for the year ending December 31, 2025. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.","length":572,"tagName":"p"},{"type":"text","content":"“We are building meaningful momentum as we further advance our first-in-class portfolio of potential medicines targeting cancers with significant unmet needs,” said Adrian Gottschalk, President and Chief Execut...